About the
NeLM
|
Help & Support
|
Site Feedback
|
Update Newsletter Subscription
Homepage
Login
|
Register
Search the NeLM
Medicines A-Z
Find key information about medicines by name (prototype)
Browse by Categories:
BNF Category
|
Medical Specialty
|
National Health Service
|
Medicines Information
Browse by NeLM area:
Evidence
|
Other Library Updates
|
News
|
Health In Focus
|
Medicines A-Z
|
Communities
|
Useful Links
|
Formularies
Medical Specialty
Anaesthesia
Bone Diseases
Cardiovascular Medicine
Care of Older People
Cerebrovascular Disorders
Complementary Medicine
Dentistry
Dermatology
Ear, Nose and Throat (ENT) disorders
Emergency Medicine
Endocrinology
Family planning
Gastroenterology
Geriatric Medicine
Haematology
Immunology and vaccination
Infections
Infectious Diseases
Intensive Care (ICU)
Liver disease
Menopause / hormone replacement therapy (HRT)
Mental Health
Neurology
Nutrition and Metabolism
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Pain control
Palliative care
Preventative medicines
Radiology
Renal medicine
Reproductive medicine
Respiratory Medicine
Rheumatology
Sports medicine
Surgery
Travel medicine
Urology
Wound Management
Asthma
Chronic Obstructive Airways Disease
Cystic fibrosis
Diffuse parenchymal lung disease
Lung biochemistry
Lung function
Other respiratory infections
Sleep disorders
Tuberculosis
106 library items
in Cystic fibrosis
Filter results by:
Date Published
2012 (7)
2011 (23)
2010 (20)
2009 (14)
2008 (13)
More
NeLM
Area
News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies
Results filtered by:
Category
Respiratory Medicine (
remove
)
,
Cystic fibrosis (
remove
)
Sort by:
Least recent publication date
Most recent publication date
Title alphabetical A-Z
Title alphabetical Z-A
Source alphabetical A-Z
Source alphabetical Z-A
Display summary:
No
Yes
Results 1 - 10 of 106
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next
1.
Relationship of adherence determinants and parental spirituality in cystic fibrosis
Source:
Pediatric Pulmonology
,
Date published:
18/05/2012
Category:
Compliance
|
Cystic fibrosis
|
Paediatrics
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link
2.
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe
Source:
Respiratory Medicine
,
Date published:
27/04/2012
Category:
Cystic fibrosis
|
European Agency for the Evaluation of Medicinal Products (EMEA)
|
Respiratory Medicine
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link (ScienceDirect)
3.
Timing of hypertonic saline inhalation for cystic fibrosis
Source:
Cochrane
,
Date published:
01/03/2012
Category:
3.1.5 Peak flow meters, inhaler devices and nebulisers
|
Cystic fibrosis
|
Drug reviews
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to Abstract
4.
Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols
Source:
Thorax
,
Date published:
01/03/2012
Category:
5.1.4 Aminoglycosides
|
5.1.7 Some other antibacterials
|
Bacterial
|
Cystic fibrosis
|
Other respiratory infections
NeLM
Area:
News
Abstract (full text available to subscribers only)
5.
Colistimethate sodium (Colobreathe®) dry powder inhaler approved in the EU for CF patients with chronic P. aeruginosa lung infection
Source:
BioSpace
,
Date published:
27/02/2012
Category:
5.1.7 Some other antibacterials
|
Cystic fibrosis
|
European Agency for the Evaluation of Medicinal Products (EMEA)
|
New drugs
NeLM
Area:
News
Link
6.
SMC does not recommend aztreonam lysine (Cayston™) for pulmonary infections in cystic fibrosis
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
14/02/2012
Category:
5.1.2 Cephalosporins, carbapenems, and other beta-lactams
|
Cystic fibrosis
|
Drug reviews
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link
7.
Horizon scanning: US FDA approves ivacaftor (Kalydeco®) for the treatment of rare form of cystic fibrosis
Source:
FDA
,
Date published:
01/02/2012
Category:
Cystic fibrosis
|
New drugs
NeLM
Area:
News
FDA Report
BioSpace report
8.
Horizon scanning: Licensing application for ivacaftor (KalydecoTM), the first potential medicine to target underlying cause of cystic fibrosis, accepted by FDA and EMA
Source:
BioSpace
,
Date published:
16/12/2011
Category:
3.7 Mucolytics
|
Cystic fibrosis
|
European Agency for the Evaluation of Medicinal Products (EMEA)
|
Food &Drug Administration (FDA)
|
New drugs
NeLM
Area:
News
Link
Link to NeLM report of RCT
9.
Horizon scanning: RCT investigates use of ivacaftor in patients with cystic fibrosis and the G551D mutation
Source:
N Engl J Med
,
Date published:
03/11/2011
Category:
Cystic fibrosis
|
New drugs
NeLM
Area:
News
Abstract (full text – subscribers only)
Editorial (subscribers only)
Previous NeLM news report
10.
Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis
Source:
Journal of Pediatrics
,
Date published:
31/10/2011
Category:
5.1 Antibacterial drugs
|
Cystic fibrosis
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link (ScienceDirect)
Results 1 - 10 of 106
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next